Inflammatory Bowel Disease and Thromboembolic Events

The main objective was to demonstrate the existence and importance of hypercoagulability in patients with IBD, by determining the prevalence of changes in coagulation parameters and evaluating the impact of these changes on the occurrence of thromboembolic events.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Inflammatory Bowel Diseases Cardiovascular Diseases Coagulation Disorder Digestive System Diseases Embolism and Thrombosis Gastroenteritis Gastrointestinal Diseases Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Intestinal Diseases Thromboembolism Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centro Hospitalar Tondela Viseu

Viseu, 3504-509, Portugal

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with 18 years of age or older, diagnosed with IBD, followed at a gastroenterology consultation at Centro Hospitalar Tondela-Viseu, between November 2016 and April 2017.

Exclusion criteria

Individuals with other risk factors for TE (severe hepatic or renal failure, valvular heart disease, atrial fibrillation, heart failure or cardiomyopathy, pregnancy, and oral anticoagulants or heparin at the baseline).

Treatment and study plan

No intervention was made

Other

No intervention was made

Primary outcomes

Prevalence of thromboembolic events in IBD

Time frame: 36 months

To evaluate the coagulation parameters and the prevalence of thromboembolic events in IBD patients
Coagulation parameters variations in IBD

Time frame: 36 months

To investigate the correlation between coagulation parameters and disease phenotype and activity.

Sponsors and collaborators

Lead sponsor

Centro Hospitalar Tondela-Viseu

Other

Collaborators

Portuguese IBD Group

Registry information

Important dates

Study start: 2016
Primary completion: 2020
Study completion: 2020
First posted: Dec 17, 2021
Registry last updated: Dec 17, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed